| |  Online-Ressource |
|---|
| Verfasst von: | Borgoni, Simone [VerfasserIn]  |
|---|
| | Sofyali, Emre [VerfasserIn] |
|---|
| | Soleimani Dodaran, Maryam [VerfasserIn] |
|---|
| | Wilhelm, Heike [VerfasserIn] |
|---|
| | Müller-Decker, Karin [VerfasserIn] |
|---|
| | Will, Rainer D. [VerfasserIn] |
|---|
| | Noronha, Ashish [VerfasserIn] |
|---|
| | Beumers, Lukas [VerfasserIn] |
|---|
| | Verschure, Pernette Jeanine [VerfasserIn] |
|---|
| | Yarden, Yosef [VerfasserIn] |
|---|
| | Magnani, Luca [VerfasserIn] |
|---|
| | Kampen, Antoine van [VerfasserIn] |
|---|
| | Moerland, Perry D. [VerfasserIn] |
|---|
| | Wiemann, Stefan [VerfasserIn] |
|---|
| Titel: | Time-resolved profiling reveals ATF3 as a novel mediator of endocrine resistance in breast cancer |
|---|
| Verf.angabe: | Simone Borgoni, Emre Sofyalı, Maryam Soleimani, Heike Wilhelm, Karin Müller-Decker, Rainer Will, Ashish Noronha, Lukas Beumers, Pernette J. Verschure, Yosef Yarden, Luca Magnani, Antoine H. C. van Kampen, Perry D. Moerland and Stefan Wiemann |
|---|
| E-Jahr: | 2020 |
|---|
| Jahr: | 11 October 2020 |
|---|
| Umfang: | 19 S. |
|---|
| Fussnoten: | Gesehen am 26.11.2020 |
|---|
| Titel Quelle: | Enthalten in: Cancers |
|---|
| Ort Quelle: | Basel : MDPI, 2009 |
|---|
| Jahr Quelle: | 2020 |
|---|
| Band/Heft Quelle: | 12(2020,10) Artikel-Nummer 2918, 12 Seiten |
|---|
| ISSN Quelle: | 2072-6694 |
|---|
| Abstract: | Breast cancer is one of the leading causes of death for women worldwide. Patients whose tumors express Estrogen Receptor α account for around 70% of cases and are mostly treated with targeted endocrine therapy. However, depending on the degree of severity of the disease at diagnosis, 10 to 40% of these tumors eventually relapse due to resistance development. Even though recent novel approaches as the combination with CDK4/6 inhibitors increased the overall survival of relapsing patients, this remains relatively short and there is a urgent need to find alternative targetable pathways. In this study we profiled the early phases of the resistance development process to uncover drivers of this phenomenon. Time-resolved analysis revealed that ATF3, a member of the ATF/CREB family of transcription factors, acts as a novel regulator of the response to therapy via rewiring of central signaling processes towards the adaptation to endocrine treatment. ATF3 was found to be essential in controlling crucial processes such as proliferation, cell cycle, and apoptosis during the early response to treatment through the regulation of MAPK/AKT signaling pathways. Its essential role was confirmed in vivo in a mouse model, and elevated expression of ATF3 was verified in patient datasets, adding clinical relevance to our findings. This study proposes ATF3 as a novel mediator of endocrine resistance development in breast cancer and elucidates its role in the regulation of downstream pathways activities. |
|---|
| DOI: | doi:10.3390/cancers12102918 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.3390/cancers12102918 |
|---|
| | Volltext: https://www.mdpi.com/2072-6694/12/10/2918 |
|---|
| | DOI: https://doi.org/10.3390/cancers12102918 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | ATF3 |
|---|
| | breast cancer |
|---|
| | drug-resistance |
|---|
| | endocrine therapy |
|---|
| | RPPA |
|---|
| K10plus-PPN: | 1741171741 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Time-resolved profiling reveals ATF3 as a novel mediator of endocrine resistance in breast cancer / Borgoni, Simone [VerfasserIn]; 11 October 2020 (Online-Ressource)
